Clicky

Sarepta Therapeutics, Inc.(SRPT) News

Date Title
Apr 8 Why Sarepta's First-Quarter Report Is Already Dead In The Water: Analyst
Apr 6 2 Biotech Stocks to Buy Hand Over Fist in April
Apr 2 Outperforming ETF manager names a potential ‘50-bagger’ in the stock market
Mar 29 Sarepta Therapeutics (SRPT) Up 1.2% Since Last Earnings Report: Can It Continue?
Mar 29 Sarepta Therapeutics' (NASDAQ:SRPT) growing losses don't faze investors as the stock increases 3.6% this past week
Mar 25 A Comprehensive Look at Sarepta's Growth and Innovation
Mar 17 30 Biggest Biotechnology Companies in the World
Mar 14 Billionaire Ken Fisher and Corporate Insiders Are Buying These 10 Stocks
Mar 13 Does This 1 New Threat Make Sarepta Therapeutics Stock Worth Selling?
Mar 12 Director Wigzell Hans Lennart Rudolf Sells 15,000 Shares of Sarepta Therapeutics Inc (SRPT)
Mar 11 Billionaire Ray Dalio and Insiders Love These 10 Stocks
Mar 7 Director Stephen Mayo Sells 3,135 Shares of Sarepta Therapeutics Inc (SRPT)
Mar 4 Sarepta Therapeutics Stock Has 73% Upside, According to 1 Wall Street Analyst
Mar 4 Sarepta Therapeutics to Present at Upcoming Investor Conferences
Feb 23 The Zacks Analyst Blog Highlights Moderna, RAPT Therapeutics, Iovance, Sarepta Therapeutics and Regeneron
Feb 21 Sarepta (SRPT) to Report Q4 Earnings: Will It Beat Estimates?
Feb 21 Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2023 Financial Results
Feb 20 Sarepta Therapeutics (SRPT) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
Jan 16 Adaptimmune (ADAP) Surges More Than 80% in a Month: Here's Why
Jan 16 Sarepta Therapeutics Initiates Screening in EMERGENE, a Phase 3 Clinical Study of SRP-9003 for the Treatment of Limb-Girdle Muscular Dystrophy Type 2E/R4